Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

One silver lining, potentially, is that the first few capital raises ADXS did in late 2013 and 2014 included warrants, which could have contributed to the upward push of the stock (peaking at $30) as participants drove the stock up, sold warrants to lock in profit then shorted the stock back down. It's good that short interest has nearly all been closed out at this point as the stock's been ridden to the ground. Let's see if this new offering/package incentivizes the players to run the stock back up.